Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biote (BTMD) Change in Accured Expenses (2021 - 2025)

Biote (BTMD) has 5 years of Change in Accured Expenses data on record, last reported at $2.4 million in Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 65.13% year-over-year to $2.4 million; the TTM value through Sep 2025 reached $3.1 million, up 278.44%, while the annual FY2024 figure was $4.6 million, 108.37% up from the prior year.
  • Change in Accured Expenses reached $2.4 million in Q3 2025 per BTMD's latest filing, up from -$1.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $4.9 million in Q3 2023 and bottomed at -$26.1 million in Q2 2022.
  • Average Change in Accured Expenses over 5 years is -$1.1 million, with a median of -$135000.0 recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: plummeted 32986.68% in 2022, then soared 358.59% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $2.7 million in 2021, then crashed by 79.64% to $555000.0 in 2022, then plummeted by 421.08% to -$1.8 million in 2023, then skyrocketed by 358.59% to $4.6 million in 2024, then tumbled by 47.07% to $2.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $2.4 million in Q3 2025, -$1.2 million in Q2 2025, and -$2.7 million in Q1 2025.